1. Medtech Insight
  2. >>Business
  3. >>Deals

Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer

 
• By Catherine Longworth

Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.

pathdoc/Shutterstock.com

Qiagen NV has terminated its agreement to be acquired by Thermo Fisher Scientific after shareholders rejected an amended offer price.

On 16 July, Thermo Fisher Scientific and Qiagen announced an amendment to the original $11.5bn buyout announced in March. Thermo Fisher Scientific increased the offer from €39.00 per share in cash to a new price of €43.00, but Qiagen shareholders said the price still fell short

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.